Chest:淋巴结受累范围或可预测非小细胞肺癌患者的预后

2013-12-27 佚名 丁香园

研究要点: 1)该研究评估淋巴结受累范围和其他预后因素在预测中国Ⅱ-N1期非小细胞肺癌患者确定性手术后结局中的意义; 2)发现肿瘤体积和淋巴结受累范围是整体生存期和无病生存期的重要预测因子。 在2009年发布的第7版国际抗癌联盟和美国癌症联合委员会癌症分期手册中,非小细胞肺癌(NSCLC)分期系统对当前的NSCLC淋巴结转移描述没有做任何修改。然而,NSC

研究要点:

1)该研究评估淋巴结受累范围和其他预后因素在预测中国Ⅱ-N1期非小细胞肺癌患者确定性手术后结局中的意义;

2)发现肿瘤体积和淋巴结受累范围是整体生存期和无病生存期的重要预测因子。

在2009年发布的第7版国际抗癌联盟和美国癌症联合委员会癌症分期手册中,非小细胞肺癌(NSCLC)分期系统对当前的NSCLC淋巴结转移描述没有做任何修改。然而,NSCLC患者淋巴结受累范围(包括受累淋巴结区、受累淋巴结比例和数目)的预后意义尚不清楚。

为了评估淋巴结受累范围和其他因素对确定性手术后的中国Ⅱ-N1期NSCLC患者预后的意义,来自上海交通大学附属上海市胸科医院的陆舜教授及其团队进行了一项研究,研究结果发表在2013年10月的Chest杂志上。研究发现,N1淋巴结转移、受累淋巴结比例和肿瘤大小可以为Ⅱ期NSCLC患者提供独立的预后信息。

该研究回顾性分析了1999年至2009年期间,在上海市胸科医院进行完全手术切除的206例Ⅱ期(T1a-T2bN1M0)NSCLC患者的临床病理特征。使用Kaplan-Meier统计分析比较整体生存期(OS)和无病生存期(DFS)。使用分层回归分析和Cox回归分析评估淋巴结受累与生存期之间的关系。

该研究结果表明,单因素分析显示,外周淋巴结受累、受累淋巴结比例、肿瘤体积小和鳞状细胞癌可作为有统计学意义的指标预测较长的整体生存期和无病生存期。单因素分析同样证实脏层胸膜受累也可以作为一个有统计学意义的指标预测无病生存期。多因素分析显示肿瘤体积和淋巴结受累区域是整体生存期的重要预测因子。

该研究提示, N1淋巴结转移、受累淋巴结比例和肿瘤大小可以为Ⅱ期非小细胞肺癌患者提供独立的预后信息。

研究背景:

肺癌是世界范围内癌症相关死亡的主要原因。手术切除癌症组织是早期非小细胞肺癌的标准治疗方法。准确的淋巴结受累分期在小细胞肺癌患者起始治疗中是至关重要的。这经常影响治疗方法和治疗时机的决策。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050385, encodeId=0d0f2050385fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jul 10 23:35:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929202, encodeId=ba5e1929202e0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 21 01:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990526, encodeId=f505199052619, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jul 04 18:35:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059452, encodeId=bcbd2059452cd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 25 21:35:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292943, encodeId=bf45129294378, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600795, encodeId=46871600e957b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050385, encodeId=0d0f2050385fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jul 10 23:35:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929202, encodeId=ba5e1929202e0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 21 01:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990526, encodeId=f505199052619, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jul 04 18:35:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059452, encodeId=bcbd2059452cd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 25 21:35:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292943, encodeId=bf45129294378, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600795, encodeId=46871600e957b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=)]
    2014-08-21 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050385, encodeId=0d0f2050385fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jul 10 23:35:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929202, encodeId=ba5e1929202e0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 21 01:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990526, encodeId=f505199052619, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jul 04 18:35:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059452, encodeId=bcbd2059452cd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 25 21:35:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292943, encodeId=bf45129294378, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600795, encodeId=46871600e957b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050385, encodeId=0d0f2050385fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jul 10 23:35:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929202, encodeId=ba5e1929202e0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 21 01:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990526, encodeId=f505199052619, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jul 04 18:35:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059452, encodeId=bcbd2059452cd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 25 21:35:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292943, encodeId=bf45129294378, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600795, encodeId=46871600e957b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050385, encodeId=0d0f2050385fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jul 10 23:35:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929202, encodeId=ba5e1929202e0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 21 01:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990526, encodeId=f505199052619, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jul 04 18:35:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059452, encodeId=bcbd2059452cd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 25 21:35:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292943, encodeId=bf45129294378, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600795, encodeId=46871600e957b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=)]
    2013-12-29 sodoo
  6. [GetPortalCommentsPageByObjectIdResponse(id=2050385, encodeId=0d0f2050385fa, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jul 10 23:35:00 CST 2014, time=2014-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929202, encodeId=ba5e1929202e0, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Aug 21 01:35:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990526, encodeId=f505199052619, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jul 04 18:35:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059452, encodeId=bcbd2059452cd, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 25 21:35:00 CST 2014, time=2014-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292943, encodeId=bf45129294378, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600795, encodeId=46871600e957b, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Sun Dec 29 05:35:00 CST 2013, time=2013-12-29, status=1, ipAttribution=)]

相关资讯

Ann Surg:淋巴结状态为早期食管腺癌患者食管切除治疗后生存与复发**预后因素

研究要点:1.本研究旨在确定接受食管切除治疗的早期食管腺癌患者相关预后风险因素;2.N+病情与肿瘤浸润深度增加、淋巴血管浸润、肿瘤分化情况及血管浸润间存在显著关联;3.淋巴结状态为生存率与复发率相关唯一独立风险因素;肿瘤浸润深度与淋巴结转移率有关,但深层黏膜与黏膜下层浸润间并无明确的界值。尽管内窥镜食管切除(ER)已成为一种更普遍接受的针对限于黏膜的早期食管腺癌(eACE)治疗手段,但根据相关报告

ATS:王邵华等发现淋巴结转移是影响PMME预后的独立危险因素

原发性食管恶性黑色素瘤(PMME)是一种非常少见的恶性肿瘤,伴有转移、进展倾向,临床预后较差。迄今为止原发性食管恶性黑色素瘤的的报导较少,那些因素影响其临床预后还未见明确报道。针对这种情况,来自上海市第一人民医院胸外科的王邵华教授和日本东京国家癌症中心医院食管外科部的Tsukiji教授等人对PMME患者的临床资料进行回顾性分析,研究结果发表于2013年4月29日的《胸外科年鉴》(Ann Thora

Ann Thorac Surg:胸腺癌术中淋巴结清扫可使患者获益

对于肿瘤患者而言,淋巴结清扫在其手术中起着重要的作用。然而淋巴结清扫在胸腺癌中的作用方面数据仍比较缺乏。针对这种情况,来自韩国首尔国立大学医院的首尔国立大学医院In Kyu Park教授等人进行了一项研究,研究结果在线发表于2013年7月24日的《胸外科年鉴》(Annals of Surgical)杂志上。作者发现广泛的淋巴节清扫,10个以上淋巴结,才能准确地预测患者的预后。同时,前纵隔及右气管旁

ASO:淋巴结跳跃性转移并非胸段食管鳞状细胞癌预后的预测因素

相关研究发现,淋巴结跳跃性转移(NSM)对于非小细胞肺癌具有重要的临床价值,但目前对食管癌NSM的相关研究较为匮乏。为此,我国复旦大学附属肿瘤医院相加庆副教授及付小龙教授等人进行了一项研究,该研究旨在筛选出影响NSM的风险因素,并对NSM在胸段食管鳞状细胞癌中的预后价值做出评价。该研究结果发表于2013年5月18日在线出版的《外科肿瘤学年鉴》(Annals of Surgical Oncology

Ann Thorac Surg:高手术风险NSCLC接受肺段切除有助于淋巴结分期和边缘切除

早期肺癌和肺储备功能有限的患者可能不是肺叶切除术的合适人选。在这种情况下,一般进行亚肺叶切除(楔形或肺段切除)。许多医生认为肺段切除具有优越性,因为它可以改善切缘和淋巴结取样。但在这方面数据仍比较缺乏。针对这种情况,来自波士顿的贝斯以色列女执事医疗中心外科部的MichaelKent博士等人进行了一项研究,研究结果在线发表于2013年8月30日的《胸外科年鉴》(AnnThoracSurg)杂志上。作

ASO:乳腺癌亚型并非局部控制的有效预测变量

尽管目前认为,免疫组化染色法确定的乳腺癌亚型(BCS)与分子亚型及患者预后和结局有关,但BCS与腋窝淋巴结侵犯间关系的文献却较为匮乏。为此,美国耶鲁大学医学院的Meena S. Moran博士等人进行了一项研究,该研究旨在评价BCS是否可以预测淋巴结转移,并评价BCS是否与其他临床病理学表现特征存在关联。这项研究结果发表于2013年5月10日在线出版的《外科肿瘤学年鉴》(Annals of Sur